Skip to content
Catalyst Biosciences
Primary Menu
About
Overview
Management Team
Board of Directors
Pipeline
Overview
Complement
Partnering Opportunties
Science
Overview
Publications
Clinical Trials
Investors
Press Releases
Events and Presentations
Events
Presentations
Scientific Presentations and Publications
Financials & Filings
Stock Information
Stock Quote
Stock Chart
Corporate Governance
Leadership Team
Board of Directors
Committee Composition
Investor FAQ
Careers
Career Opportunities
Benefits
Values
Contact
Discovery and Planned Optimization of a Complement Factor C3-Inactivating Alterase, CB-2782
Post navigation
Previous:
Pharmacokinetics and Pharmacodynamics of daily Subcutaneously Administered CB2679D/ISU304 in Hemophilia B Dogs
Next:
Phase 1/2 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant Cb2679d/ISU304: Pharmacokinetics and Safety
X
Previous
Next
